<?xml version="1.0" encoding="UTF-8"?>
<ref id="B15">
 <label>15.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Reisinger</surname>
    <given-names>EC</given-names>
   </name>
   <name>
    <surname>Tschismarov</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Beubler</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Wiedermann</surname>
    <given-names>U</given-names>
   </name>
   <name>
    <surname>Firbas</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Loebermann</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial</article-title>. 
  <source>Lancet.</source> (
  <year>2019</year>) 
  <volume>392</volume>:
  <fpage>2718</fpage>â€“
  <lpage>27</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32488-7</pub-id>
  <?supplied-pmid 30409443?>
  <pub-id pub-id-type="pmid">30409443</pub-id>
 </mixed-citation>
</ref>
